University of California Davis

Plus: Accent’s Copeland to retire and updates from ProQR, Kashiv and Aculeus

BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos

Boston, Mass.-based neuropsychiatry company is developing non-hallucinogenic compounds that promote neuroplasticity  

Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature

Modalis accomplishes gene activation, while Tune achieves gene repression, both in non-human primates

Plus: Updates from Magenta, CSL, Hemgenix, Affimed, Kymera and more

Plus Biogen, Eisai seeking approval of lecanemab for Alzheimer’s, Transcenta IPO, ViiV, Innovent-Union and more

InterVenn builds on research by scientific founders Bertozzi, Lebrillo to develop glycoproteomic cancer diagnostics

Indapta streamlines universal allogeneic NK cell development by forgoing genetic engineering